Antibiotics with new mechanisms of action are urgently required to combat the growing health threat posed by resistant pathogenic microorganisms. We synthesized a family of peptidomimetic antibiotics, based on the antimicrobial peptide protegrin I. Several rounds of optimization gave a lead compound that was active in the nanomolar range against gram-negative Pseudomonas sp., but was largely inactive against other Gram-negative and Gram-positive bacteria. Biochemical and genetic studies showed the peptidomimetics had a non-membrane-lytic mechanism of action and identified a homologue of the ß-barrel protein LptD (Imp/OstA), which functions in outer membrane biogenesis, as a cellular target. The peptidomimetic showed potent antimicrobial activity in a mouse septicemia infection model. Drug-resistant strains of Pseudomonas are a serious health problem, so this family of antibiotics may have important therapeutic applications. A synthesized antibiotic targets a protein involved in outer membrane biogenesis to selectively kill Pseudomonas pathogens.
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Peptidomimetic Antibiotics Target Outer Membrane Biogenesis in
Pseudomonas aeruginosa
A synthesized antibiotic targets a protein involved in outer membrane biogenesis to selectively kill Pseudomonas pathogens.
Abstract
Antibiotics with new mechanisms of action are urgently required to combat the growing health threat posed by resistant pathogenic microorganisms. We synthesized a family of peptidomimetic antibiotics, based on the antimicrobial peptide protegrin I. Several rounds of optimization gave a lead compound that was active in the nanomolar range against gram-negative Pseudomonas sp., but was largely inactive against other Gram-negative and Gram-positive bacteria. Biochemical and genetic studies showed the peptidomimetics had a non-membrane-lytic mechanism of action and identified a homologue of the ß-barrel protein LptD (Imp/OstA), which functions in outer membrane biogenesis, as a cellular target. The peptidomimetic showed potent antimicrobial activity in a mouse septicemia infection model. Drug-resistant strains of Pseudomonas are a serious health problem, so this family of antibiotics may have important therapeutic applications.
Naturally occurring peptides and proteins make interesting starting points for the design and synthesis of biologically active peptidomimetics. We previously synthesized libraries of ß-hairpin-shaped peptidomimetics (1, 2) based on the membranolytic host-defense peptide protegrin I (PG-I) (3). These mimetics contain loop sequences related to that in PG-I, but linked to a D-Proline-L-Proline template, which helps to stabilize ß-hairpin conformations within the macrocycle (4, 5) (Fig. 1A) . One sequence variant L8-1 had broad-spectrum antimicrobial activity like PG-I, but with a reduced hemolytic activity on human red blood cells (2) . To optimize this lead, we performed iterative cycles of peptidomimetic library synthesis and screening for improved antimicrobial activity. The optimal hit from each library was used as a starting point for the synthesis and testing of variations in a subsequent library. This structureactivity trail led sequentially to mimetics L19-45, L26-19 and L27-11 ( Fig. 1 ). L27-11 possessed an interesting spectrum of antimicrobial activity, including minimal inhibitory concentrations (MICs) in the nanomolar range against many Pseudomonas aeruginosa (PA) strains and other Pseudomonas sp.; the mimetic is only weakly active or inactive against other Gram-positive and
Gram-negative bacteria (Table 1 ( 6) ). In contrast, PG-I displays broad spectrum antimicrobial activity against Gram-positive and Gram-negative bacteria in the low micromolar range (7) . The enantiomeric (mirror image) form of L27-11 is essentially inactive (MIC ≥ 32 µg/ml) against PA, unlike the two enantiomers of PG-I (8), suggesting that the antibacterial target of the mimetic is chiral and not the achiral lipid chains of the cell membrane targeted by PG-I (9-12).
Further efforts focused on optimizing plasma stability and drug-like properties. The compounds POL7001 and POL7080 displayed much improved plasma half-lives whilst retaining a potent and selective action against PA; the MICs covering 90% of more than 100 PA clinical isolates tested (MIC 90 ) were 0.13 and 0.25 µg/ml, respectively, for these two mimetics.
We next focused on identifying the mechanism of action of this family of peptidomimetics. Their mode of action against PA at concentrations close to the MIC was clearly different from the rapid membranolytic actions of both PG-I (7) and polymyxin B, a cationic macrocyclic peptide antibiotic of bacterial origin (13). Whereas PG-I or polymyxin at 4x MIC caused rapid cell lysis, the killing caused by the peptidomimetics was much slower (Fig. 1B) .
The ability of the peptidomimetics to permeabilize the PA cell membrane was also tested using the fluorescent nucleic acid stain SYTOX (14) . No significant fluorescence increase was apparent over 120 min when PA cells were exposed to SYTOX and L26-19, L27-11 or POL7001, compared with a rapid fluorescence increase upon exposure to PG-I or polymyxin B
( Fig. 1C (6)). A direct interaction between the peptidomimetic antibiotics and lipopolysaccharide (LPS) was examined using a dansyl-polymyxin displacement binding assay (15) . This revealed an interaction between LPS and L27-11 in the low micromolar range (IC 50 0.8 µM), which was not enantioselective (IC 50 1.1 µM for the enantiomer of L27-11), suggesting that LPS is not the primary site of antimicrobial action. Also, L26-19, L27-11 and POL7001 caused no significant lysis of human red blood cells at concentrations up to 100 µg/ml.
We tested whether the peptidomimetics have any effect on protein or nucleic acid biosynthesis in PA, by examining the kinetics of incorporation of radio-labeled precursors into macromolecules. No significant influence was detected (6), suggesting that inhibition of protein, DNA or RNA biosynthesis are not the primary modes of action. Similar attempts to monitor effects on cell wall biosynthesis using radio-labeled N-acetylglucosamine were frustrated by low levels of incorporation of this precursor into cell wall biopolymers.
As an alternative approach to investigate the mechanism of action, a forward genetic screen was established to characterize the genetic basis for resistance to the antibiotics.
Spontaneous resistant mutants of PA PAO1 could be selected on the antibiotic POL7080 at 5x MIC, at an estimated frequency of ≤1x10
10
. Three mutants (PAO1 RES1-3 ) showed MICs towards POL7080 and L26-19 of >32 µg/ml, but were more sensitive towards POL7001 (MIC 8 µg/ml, vs. 0.06 µg/ml for wild-type (wt) PA PAO1). No other changes in growth rate were observed.
Compared to wt PA PAO1 the mutants showed only minor changes in sensitivity towards several other antibiotics (see Table 2 ). To identify the causative mutation(s), we constructed three gene appears to act as a dominant resistance marker in the wt PA PAO1 background. This does not appear to be a gene dosage effect, since introduction of the wt allele on plasmid pVLT31 (18) does not influence antibiotic sensitivity for PA PAO1 nor PAO1 RES1 . Moreover, neither wt PA PAO1 containing plasmid-borne copies of lptD1, nor PAO1 RES1 containing copies of lptD have altered sensitivity to most of the other antibiotics tested (Table 2) . This argues against a general change in the permeability of the outer membrane (OM) caused by this mutation.
LptD is an OM protein widely distributed in Gram-negative bacteria that functions in the assembly of LPS in the outer leaflet of the OM (17, (19) (20) (21) . LptD is an essential low abundance OM protein in E. coli (19) , whose depletion causes stress in OM biogenesis (21, 22) . LptD in PA PAO1 is predicted to contain a C-terminal ß-barrel domain (approx. res. 300-924) embedded in the outer membrane and an N-terminal domain (approx. res. 34-300) (19) , which may reside in the periplasm and/or partly plug the ß-barrel ( Fig. 2A) . The ß-barrel sequence is highly conserved in LptD homologs in Gram-negative bacteria (17) , although the N-terminal domain is more variable in length, comprising about 300 residues in PA but only about 180 residues in E.
coli K12 (6). The size difference in the periplasmic domains of LptD in E. coli and PA, the location within this domain of the lptD1 mutation, and the key function of LptD in OM biogenesis, suggest that LptD may be a primary target of the peptidomimetic antibiotics.
Photoaffinity labeling experiments (23) were performed to determine whether the antibiotics bind to LptD in intact cells. For this, an analogue (PAL-1) was produced containing a L-4,4-diazarinylproline (L-photo-proline) in place of L-proline, as well as a biotin tag at position-1 (MIC of PAL-1 against PA PAO1 = 0.05 µg/ml) (Fig. 1A) (6) ). Photoaffinity labeling with PAL-1 consistently revealed a major photolabeled protein with an apparent mass by SDS-PAGE of ≈100 kDa, close to that expected for PA LptD (MW calc. = 100,751) (Fig. 2B) . When the photoaffinity labeling was repeated in the presence of a 100x excess of L27-11, the labeled band disappeared from the blot, demonstrating a competition between L27-11 and PAL-1 for binding to LptD. The identity of the photolabeled protein was proven to be LptD (PA0595) using 2D gels and in-gel protease digestion/LC-ESI-MS-MS analysis, and immunoblotting using polyclonal antibodies raised against a synthetic C-terminal peptide fragment of LptD (6) . When the photolabeling experiment was repeated using the resistant PAO1 RES1 mutant, photolabeling of LptD was not detected, indicating that the protein is no longer able to bind the antibiotic with comparable affinity.
If the function of LptD is impaired upon binding to the peptidomimetic, then some effect on OM structure and biogenesis should become apparent (19, 24) . When grown in MuellerHinton (MH) broth for several hours in the presence of growth-inhibitory amounts of L27-11, PA cells became more sensitive to detergents (Triton X-100 and SDS) and to various antibiotics, including tetracycline and rifampicin (6) . PA PAO1 cells grown in MH broth with L27-11 or POL7001 were also examined in thin sections by transmission electron microscopy (EM). This revealed internal accumulation of membrane-like material in many apparently intact cells (Fig.   2C ), using two different fixation methods, an effect not seen in cells grown without the antibiotic. Similar accumulations have been observed in E. coli cells depleted of lptD (21, 22) , and in other bacteria exposed to antimicrobial peptides (25) . Some cells (≈10%) grown in this way formed filaments comprising multiple concatenated cells (Fig. 2D) , suggesting an impairment in cell-division, which was not observed with untreated PA PAO1 cells, nor with L27-11-treated PAO1 RES1 cells. Cells grown in the presence of growth-inhibitory amounts of L27-11 could be uniformly stained with the membrane dye 3,5-dipropylthiacarbocyanine (diSC 3 (5)) (Fig. 2E) , whereas untreated PA PAO1 or L27-11-treated PAOI RES1 cells exposed to this dye did not fluoresce. Thus, the action of L27-11 during growth impairs the OM permeability barrier.
Interference with the function of LptD may also allow entry of phospholipids into the outer leaflet of the OM. In E. coli and Salmonella sp. this is known to activate the OM enzyme PagP, which modifies LPS by converting the hexa-acyl form of lipid A into the hepta-acyl form by transferring a palmitate group from outer leaflet phospholipids to lipid A (26, 27) . The same effect has been observed in lptD-depleted E. coli (21) . PA can also modify its lipid A by addition of a C16 fatty acid, to generate from the normal penta-acylated form (MW 1447), a hexaacylated derivative (MW 1686) (28) . This palmitate-containing hexa-acylated form has been observed in lipid A from PA clinical isolates from cystic fibrosis (CF) patients (29), while it is normally absent from laboratory-adapted strains (such as PAO1) (28).
We first confirmed that the lipid-A prepared from LPS isolated from PA PAO1 grown containing a palmitoyl residue (6) . A further indication of a perturbed membrane structure came from fractionation of membrane extracts from cells by sucrose density ultracentrifugation.
Fractions containing LPS and LptD appeared at higher density in the gradient when they came from L27-11-cultivated cells as compared to untreated cells (6), a result similar to that reported for lptD-depleted E. coli cells (19, 21) .
A fluorescently labeled derivative Fluo-1 (Fig. 1A ) of L27-11 showed an MIC against PA PAO1 of 0.1 µg/ml, suggesting that it might label potential antibiotic binding sites. PA PAO1 cells in MH broth were incubated with Fluo-1 (5 µg/ml) for 1 h at 37 o C, washed and examined by fluorescence microscopy. The resulting fluorescence staining was not uniform over the cell surface, but rather appeared to be concentrated in spots (Fig. 2F) , suggesting a localized binding site. A similar labeling was not observed when the PA PAO1 RES1 mutant was stained in this way. 
